Miracell selected as one of the nation’s top 1000 innovative companies in the health and diagnostics sector.
[Edaily Reporter Lee Soon-yong] Stem cell company Miracell has been selected as one of the government’s “1000 Innovative Companies.”
Miracell (CEO Shin Hyun-soon) announced on the 1st that it has been selected for the third round of the “1000 Innovative Companies,” a list announced by the Financial Services Commission based on evaluations by nine government ministries, including the Ministry of Trade, Industry and Energy and the Ministry of Health and Welfare.
The “1000 Innovative Companies” list is a support system for nine ministries, including the Ministry of Trade, Industry and Energy, the Ministry of SMEs and Startups, the Ministry of Science and ICT, the Ministry of Health and Welfare, and the Ministry of Oceans and Fisheries. It selects leading innovative companies by industry and provides them with exceptional financial support to foster them as future core companies.
The program was launched on July 30, 2020, with a resolution passed at the 12th Central Economic Response Headquarters meeting.
Starting with 32 companies selected in the first round, 247 were selected in the second round, and 321 companies were selected this time.
The Financial Services Commission plans to select a total of 1,000+α representative innovative companies in each industry by 2022.
Miracell was selected as one of the “Health and Diagnostic Innovative Companies” in the health technology, medical device, and innovative pharmaceutical sectors, based on selection criteria established by the Ministry of Health and Welfare.
Miracell is a stem cell company launched in 2009 with the introduction of cell extraction technology from Harvard University.
In 2017, it successfully developed a “minimally manipulated stem cell isolation and amplification source technology,” and the Ministry of SMEs and Startups selected this technology as a technology development project for commercialization by SMEs.
In particular, based on this technology, the company successfully developed and domestically produced SMART M-CELL2, a replacement for the SmartPReP2 kit developed by the Harvard Medical School’s Immunology Research Institute in 2018 and exported worldwide.
Test results at Seoul National University Bundang Hospital showed that its performance was comparable to or even superior to that of SMART M-CELL2.
SMART M-CELL2 is a device that extracts large quantities of automatically separated stem cells by concentrating bone marrow blood extracted from the body through centrifugation. It is currently used in major hospitals both domestically and internationally.
CEO Shin Hyun-soon stated, “Being selected as a national innovative company is very significant. It has opened up new avenues for scientifically treating rare and intractable diseases, including Parkinson’s disease and intractable chronic renal failure, using stem cells.” He continued, “Stem cell therapy is a treatment that extracts bone marrow blood from the patient, concentrates it through centrifugation, extracts a large amount of stem cells, and then injects them back into the body.” He explained, “Because old cells are regenerated into healthy ones, the treatment is highly effective in improving the body’s functions.”
Smart Mcell 2, recognized as an innovative technology, is a cutting-edge system for “bone marrow and blood stem cell manufacturing,” using biological pharmaceutical manufacturing technology to extract hematopoietic stem cells (CD34+) from blood and mesenchymal stem cells from bone marrow.
Approximately 2.9 billion cells can be separated and extracted in less than an hour, with a cell viability rate of 80-98%.
Its unique feature is its automated, closed system, which prevents contact with air and prevents cell deformation.
Smart Mcell 2 is equipped with special LEDs to enhance cell activity, transitioning from analog to digital.
It also features voice support, making it a perfect fit for cutting-edge bio-healthcare medical devices.
Meanwhile, Miracell, which began its medical business in 1986, has been dedicated to research and development as a stem cell specialist since 2007.
In particular, its biological drug manufacturing technology has been certified by the Ministry of Health and Welfare as a new medical technology that helps treat conditions such as acute myocardial infarction, critical limb ischemia, and cartilage defects.
Furthermore, Miracell has secured core technologies through GMP, ISO13485, ISO9001, and CE certifications, as well as 22 patent applications for cell extraction technology.